Nuvation Bio expects gross-to-net to stabilize around 30%

Nuvation Bio anticipates its gross-to-net ratio to stabilize at approximately 30% as its drug IBTROZI shifts to over 50% TKI-naive starts. This outlook provides insight into the company's financial projections.